{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:06:14Z","timestamp":1790262374624,"version":"4.1.0"},"reference-count":17,"publisher":"Society of Nuclear Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,8,7]]},"DOI":"10.2967\/jnumed.126.272756","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:30:10Z","timestamp":1790260210000},"page":"jnumed.126.272756","source":"Crossref","is-referenced-by-count":0,"title":["Next-Generation Peptide Receptor Radionuclide Therapy: A Phase 1 Dose-Escalation and Dosimetry Study of\n                    <sup>177<\/sup>\n                    Lu-DOTA-EB-TATE"],"prefix":"10.2967","author":[{"given":"Lisa","family":"Bodei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pat","family":"Zanzonico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Krebs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Reidy-Lagunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitya","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge K.","family":"Lyashchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Sch\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"O\u2019Donoghue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"2026092407300637000_jnumed.126.272756v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70410-2"},{"key":"2026092407300637000_jnumed.126.272756v1.2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.209841"},{"key":"2026092407300637000_jnumed.126.272756v1.3","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.3390\/cancers17223632","article-title":"Emerging diagnostics and therapies in neuroendocrine neoplasms: a critical review","volume":"17","author":"Hernandez-Felix","year":"2025","journal-title":"Cancers (Basel)."},{"key":"2026092407300637000_jnumed.126.272756v1.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00652-y"},{"key":"2026092407300637000_jnumed.126.272756v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00572-6"},{"key":"2026092407300637000_jnumed.126.272756v1.6","doi-asserted-by":"crossref","first-page":"S941","DOI":"10.1016\/j.annonc.2025.08.2334","article-title":"Efficacy, safety and subgroup analysis of 177Lu-edotreotide vs everolimus in patients with grade 1 or grade 2 GEP-NETs: phase 3 COMPETE trial [abstract]","volume":"36(suppl 2)","author":"Capdevila","year":"2025","journal-title":"Ann Oncol."},{"key":"2026092407300637000_jnumed.126.272756v1.7","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2893-5"},{"key":"2026092407300637000_jnumed.126.272756v1.8","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S1470-2045(20)30323-5","article-title":"Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy","volume":"21","author":"Bodei","year":"2020","journal-title":"Lancet Oncol."},{"key":"2026092407300637000_jnumed.126.272756v1.9","doi-asserted-by":"publisher","DOI":"10.1039\/c5cs00158g"},{"key":"2026092407300637000_jnumed.126.272756v1.10","first-page":"689","article-title":"Bone marrow dosimetry for radioimmunotherapy: theoretical considerations","volume":"34","author":"Sgouros","year":"1993","journal-title":"J Nucl Med."},{"key":"2026092407300637000_jnumed.126.272756v1.11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.apsb.2024.05.022","article-title":"Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: from preclinical testing to first-in-human study","volume":"15","author":"Guo","year":"2025","journal-title":"Acta Pharm Sin B."},{"key":"2026092407300637000_jnumed.126.272756v1.12","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00259-019-04530-1","article-title":"Dose escalation of an Evans blue-modified radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors","volume":"47","author":"Liu","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026092407300637000_jnumed.126.272756v1.13","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.7150\/thno.77219","article-title":"Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors","volume":"12","author":"Jiang","year":"2022","journal-title":"Theranostics."},{"key":"2026092407300637000_jnumed.126.272756v1.14","unstructured":"Lutathera [prescribing information]. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/208700Orig1s032lbl.pdf. Accessed August 25, 2026."},{"key":"2026092407300637000_jnumed.126.272756v1.15","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.7150\/thno.94521","article-title":"First-in-human study of an optimized, potential kit-type, SSTR antagonist 68Ga-DATA5m-LM4 in patients with metastatic neuroendocrine tumors","volume":"15","author":"Zhang","year":"2025","journal-title":"Theranostics."},{"key":"2026092407300637000_jnumed.126.272756v1.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268903"},{"key":"2026092407300637000_jnumed.126.272756v1.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.248658"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.126.272756","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:30:14Z","timestamp":1790260214000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.126.272756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":17,"alternative-id":["10.2967\/jnumed.126.272756"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.126.272756","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]}}}